Skip to main navigation Skip to search Skip to main content

Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism

S. P. Burns, R. A. Iles, J. M. Saudubray, R. A. Chalmers

Research output: Contribution to journalArticlepeer-review

Abstract

Propionylcarnitine (PC) excretion has been measured during a clinical trial of metronidazole therapy in two patients with propionic acidaemia and two patients with methylmalonic aciduria. All patients were in good metabolic control and were receiving L-carnitine. While total propionate excretion was reduced by up to 40% in all four patients during metronidazole therapy, the excretion of propionylcarnitine remained largely unchanged. PC comprised up to 80% of total propionate excretion in patients with propionic acidaemia. Conclusion. These results suggest an extra-hepatic source and/or differing compartmentation for PC formation from those for the production of other metabolites of propionyl-CoA.
Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalEuropean Journal of Pediatrics
Volume155
Issue number1
DOIs
Publication statusPublished - Jan 1996
Externally publishedYes

Fingerprint

Dive into the research topics of 'Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism'. Together they form a unique fingerprint.

Cite this